Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is measure the effect of VI-0521 on kidney function.
Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of
study treatment, and after an additional 4 weeks of off-treatment recovery.